Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Batoclimab in Graves' Disease
NCT05907668Phase 2Completed
- Sponsor
- Immunovant, Inc.
- Start
- May 2023
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of batoclimab in Graves' disease, sponsored by Immunovant, Inc. Primary endpoint: Percentage of Participants Who Achieved Normalization of Free Triiodothyronine (FT3) and Free Thyroxine (FT4), or Have FT3 and/or FT4 Below the Lower Limit of Normal (LLN) Without Increase in ATD… at 24 weeks. Started May 2023; status: completed.
02
Drugs
batoclimab
03
Conditions
Graves' disease
Beyond the preview
Go deeper on NCT05907668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05907668.